Serena S. Spudich, MD Professor of Neurology Yale University New Haven, Connecticut
|
|
- Elijah Patrick
- 6 years ago
- Views:
Transcription
1 HIV Reservoirs in the Brain: Where, When, How, and What Do They Mean for Our Patients? Serena S. Spudich, MD Professor of Neurology Yale University New Haven, Connecticut FORMATTED: // Financial Relationships With Commercial Entities Dr. Spudich has no relationships with commercial entities. (Updated //) Slide of Learning Objectives After attending this presentation, learners will be able to: Describe how HIV reservoirs are established in the brain. Monitor for CSF escape in patients with neurological symptoms and treated HIV. Describe possible effects of HIV cure strategies on the brain. Slide of
2 A patient on cart has a new onset difficulty with walking and stammering speech. A brain MRI is normal. You tell him that the first step in his management should be: Slide of %. To increase the CNS penetration of his antiretroviral regimen. %. Comprehensive neuropsychological testing. %. Treatment regimen switch given concern for cart side effects. %. Lumbar puncture for cerebrospinal fluid testing. %. Physical therapy for gait training. Berlin patient revealed possibility of HIV cure, creating new critical question is the brain an HIV reservoir? Slide of Doing well off ART > 8 years No replication competent HIV Waning HIV antibodies No HIV specific T cells Slide courtesy of Steve Deeks Key questions relevant to brain reservoirs for HIV Slide of Do HIV reservoirs exist in the brain during cart? How should we optimize brain health in our patients? How/when are HIV reservoirs established in the brain? How will HIV cure strategies impact the brain?
3 Thuso: year old man with difficulty walking Slide of yo man presented / with leg weakness and balance difficulty, vague cognitive symptoms, + urinary incontinence. Diagnosed with HIV in 8, cart naïve. Labs: Plasma HIV RNA. million cps/ml and CD cells/ul. CSF microbiology all negative, except CSF HIV RNA > million cps/ml. MRI Brain (FLAIR sequence) shown below with atrophy and diffuse subcortical white matter changes. Slide 8 of Thuso: year old man with difficulty walking HIV RNA(lo Diagnosis: HIV associated dementia. QNZP Since the beginning of the epidemic, CNS involvement has been a hallmark of HIV. In some individuals, HIV particularly manifests as CNS dysfunction with profound CNS HIV replication. Days post ART initiation Do reservoirs for HIV exist within the brain in most asymptomatic patients? Digit Symbol (DSY) -8 - QNPZ summarized neurologic DSY performance Days Mechanisms of CNS HIV infection prior to ART Brain Neurotoxic products (free radicals, cytokines) Slide 9 of HIV proteins (gp, tat) Neopterin Chemokines (IP, MCP ) Blood brain barrier breakdown Blood HIV tat
4 Key questions relevant to brain reservoirs for HIV Slide of Do HIV reservoirs exist in the brain during cart? How should we optimize brain health in our patients? How/when are HIV reservoirs established in the brain? How will HIV cure strategies impact the brain? Persistent macrophage/microglial activation on cart with plasma viral suppression / HIV Slide of Positron emission tomography (PET): Abnormal brain uptake of ligand specific for activated microglial cells (> years of ART vs HIV ). Brain autopsy: Increased activated microglia (CD8+ cells) in (>. years ART vs HIV ). CSF: Elevated CSF neopterin, marker of macrophage activation, associates with detectable CSF HIV RNA by single copy assay (> years of ART). Garvey et al, AIDS. ; Anthony et al, J Neuropath Exp Neur, ; Dahl et al, AIDS. HIV DNA detected in brain on ART with plasma viral suppression (sudden death) Slide of HIV RNA seldom measurable in brain Slide and data courtesy of Joe Wong Wong, Yukl, et al, Keystone HIV Persistence Conference, April
5 Persistent CNS HIV replication on ART with plasma viral suppression: CNS escape Slide of Lamivudine Abacavir Lopinavir/r hand tremor, ataxia, slurred speech, aphasia Latest CD 8 cells/ul; nadir CD cells/ul Peluso et al., AIDS,. Persistent CNS HIV replication on ART with plasma viral suppression: CNS escape Slide of CSF HIV RNA CSF WBC = cells/ul Peluso et al., AIDS,. Persistent CNS HIV replication on ART with plasma viral suppression: CNS escape PI: IV, KR, MI, IV, LP, V8A RT: ML, ED, DN, V8I, M8V, LW, TY Abacavir Lamivudine Darunavir/r Nevirapine Zidovudine Resolution of signs and symptoms Zidovudine Didanosine Lamivudine Stavudine Abacavir Tenofovir Nevirapine Delavirdine Efavirenz Saquinavir Indinavir Ritonavir Nelfinavir Amprenavir Lopinavir/r Atazanavir Possible Possible Slide of No Evidence of No Evidence of No Evidence of Possible Possible Peluso et al., AIDS,.
6 Log Log HIV HIV viral viral load load (RNA (RNA copies/ cp/ml) THINC Subject : CSF escape at two time intervals Pre- HAART T T St ar t ed DRV/ r/ TDF/ FTC years after diagnosis Blood plasma CSF Months on HAART Slide of Persistent CNS HIV replication on ART with plasma viral suppression: CNS escape Perc ent Infectivity at Low CD Elevated macrophage tropism of CSF escape population Ba L JRCSF D E9 F A UNC Joseph et al., THINC study Jake: Young man with recent infection, hesitant to start ART 9 yo man diagnosed in May,, probable acute HIV syndrome in Oct. On no meds, works as an electrical engineer; lives alone and has good support network. He wants to avoid treatment as long as possible. / / 9/ CD count 8 CD % HIV RNA 9 Slide of Key questions relevant to brain reservoirs for HIV Slide 8 of Do HIV reservoirs exist in the brain during cart? How should we optimize brain health in our patients? How/when are HIV reservoirs established in the brain? How will HIV cure strategies impact the brain?
7 HIV traffics into the CNS in early infection Slide 9 of 8 HIV RNA Levels Plasma log copies/ml 9 8 Days Post HIV Transmission HIV traffics into the CNS in early infection Slide of 8 HIV RNA Levels Plasma CSF log copies/ml 9 8 Days Post HIV Transmission HIV traffics into the CNS in early infection Slide of 8 HIV RNA Levels CSF log copies/ml 9 8 Days Post HIV Transmission
8 CSF Neopterin Slide of Macrophage activation in the CNS is triggered in early infection 8 nmol/l 9 8 Days Post HIV Transmission Neopterin, biomarker of macrophage activation, is elevated in the CNS compared to HIV negative (dotted line) throughout early infection. Neuronal injury begins during early infection Slide of CSF NFL ng/l HIV- Acute AHI Primary PHI Chronic CHI HIV HIV HIV Neurofilament Light Chain (NFL) specific CSF biomarker of axonal injury Peluso et al., JID Slide of 8 HIV RNA Levels CSF log copies/ml 9 8 Days Post HIV Transmission 8
9 Local CNS HIV replication can be established during early infection Slide of Compartmentalized evolution of CSF HIV beginning ~ months post infection TMRCA time to most recent common ancestor Sturdevant C., PloS Pathogens Key questions relevant to brain reservoirs for HIV Slide of Do HIV reservoirs exist in the brain during cart? How should we optimize brain health in our patients? How/when are HIV reservoirs established in the brain? How will HIV cure strategies impact the brain? How will HIV cure strategies affect the CNS? ART cure intervention ART Interruption ART Slide of Pre ART On ART During intervention/ before ATI At plasma rebound (or before) On ART in follow up protocol CSF: inflammatory markers, virology, injury markers Neuroimaging: MRS, volumetrics, DTI & rs fmri at Tesla magnet strength Clinical: Neurological exams & neuropsychological assessments Collaborators: V. Valcour, J. Ananworanich 9
10 SEARCH : HIV cure intervention with HDAC inhibitor, followed by treatment interruption HIV RNA (cps/ml) A. Plasma HIV RNA Baseline Wk VHM ATI On ART HIV RNA (cps/ml) C. CSF HIV RNA Single Copy Assay Baseline Wk VHM ATI Slide 8 of A. CSF Protein B. CSF IP-/CXCL p =. Protein (mg/dl) IP-/CXCL (pg/ml) Baseline Wk VHM ATI Baseline Wk VHM ATI VHM: Vorinostat (HDAC inhibitor) + Hydroxychloroquine + Maraviroc Kroon, et al., IAS Cure Symposium & IAS, Key questions relevant to brain reservoirs for HIV Slide 9 of Do HIV reservoirs exist in the brain during cart? How should? we optimize brain health in our patients? How/when are HIV reservoirs established in the brain? How will HIV cure strategies impact the brain? Start cart treatment early CSF Neuronal Injury Marker (NFL) Post ART Trailmaking A Post ART in Acute HIV Slide of After months of cart started in acute HIV (Thailand): No CSF signs of neuronal injury. Preserved normal cognitive test performance. Normal cognitive performance in individuals starting ART within months of infection (USA). Peluso et al.,jid; Kore JAIDS ; Evering et al., AIDS.
11 Encourage cart adherence CSF HIV rebound accompanied by marked CNS inflammation after ART interruption HIV RNA (log cps/ml) HIV RNA (log cps/ml) Plasma HIV RNA Slide of 8 CSF HIV RNA 8 CSF WBCs cells/ L Price, Deeks, J Neurovirology. 8 Days Investigate whether CNS cart exposure matters Impact of higher CNS Penetration Effectiveness (CPE) regimens Lower CSF viral load (Letendre CROI, Marra AIDS 9) Worsened neuropsychological performance (Marra AIDS, 9). Better neuropsychological improvement in impaired subjects (Tozzi J AIDS, 9; Smurzynski AIDS, ). Slide of Monotherapy or dual therapy increased risk of CSF escape? (Ferretti Seminars Neurol ) Potential neurotoxicity of ART: efavirenz (Leutscher Scand J Infect Dis ; Ciccarelli Neurology ),? Integrase inhibitors? Slide of Investigate whether CNS cart exposure matters ACTG A: Effects of ART intensification on the brain Randomized, placebo controlled, double blinded phase IV clinical trial, 9 weeks Study Population (n=8; arms=) Mild neurocognitive impairment (includes neuroasymptomatic) On stable ART treatment > year Plasma HIV RNA less than copies/ml Study Regimens A: No intensification B: Intensification with DTG C: Intensification with DTG and MVC Weill Cornell Uptown Site E 8 th St at York Avenue Valery Hughes, FNP 9 Weill Cornell Chelsea Site W rd St between th and th Todd Stroberg, RN 98 New Jersey Medical Center Site Bergen Street, Newark Susana Rivera BSN, RNC 9 9 9
12 Clinical guidelines for HIV and the brain in Slide of USA HIV treatment guidelines ( Treat all individuals at the time of HIV diagnosis. HIV guidelines now incorporate CNS considerations: Due to CNS toxicities, efavirenz no longer in first line recommended regimens. Treatment recommendations for HIV Associated Dementia (no efavirenz, favor regimens with higher presumed CNS penetration). Evaluation/treatment of symptomatic CNS escape including lumbar puncture for CSF viral load, CSF drug resistance testing and consideration of CNS penetration. Acknowledgements Yale: Michael Kozal Brinda Emu Leah Le Jen Chiarella Barbara Turcotte Laurie Andrews Sebastian Urday Michael Peluso Andrew Young Joome Suh Idil Kore Elham Rahimy Andrew Silverman Tess O Meara UCSF/San Francisco: Victor Valcour Joanna Hellmuth Collin Adams Lauren Wendelken Richard W. Price Evelyn Lee Julia Peterson Rick Hecht Chris Pilcher UCSF Options Study Magnet Staff Teri Liegler Study Participants UNC: Ron Swanstrom Sarah Joseph Christa Sturdevant Gretja Schnell Kevin Robertson Joe Eron THINC team Sydney: Bruce Brew Sarah Palmer Innsbruck: Dietmar Fuchs WRAIR/MHRP Jintanat Ananworanich Sodsai Tovanabutra Gustavo Kijak Suteeraporn Pinyakorn Nelson Michael Jerome Kim Merlin Robb U. Gothenburg: Lars Hagberg Magnus Gisslen Funding Support Henrik Zetterberg Milan: Paola Cinque NIH RMH RMH9999 RMH8 RMH9 R NS89 KMH W8XWH ; IAA number NIAID Y AI US Military HIV Research Program Slide of Study Participants Thai Red Cross AIDS Res Center/SEARCH Nittaya Phanuphak Praphan Phanuphak Mark de Souza Frits van Griensven James Fletcher Eugene Kroon Donn Colby Carlo Nitiya Chomchey Duanghathai Suttichom Somprartthana Rattanamanee Peeraya Mungu Putthachard Saengtawan Tippawan Pankam A patient on cart has a new onset difficulty with walking and stammering speech. A brain MRI is normal. You tell him that the first step in his management should be: Slide of %. To increase the CNS penetration of his antiretroviral regimen. %. Comprehensive neuropsychological testing. %. Treatment regimen switch given concern for cart side effects. 8%. Lumbar puncture for cerebrospinal fluid testing. %. Physical therapy for gait training.
13 Slide of A patient on cart has a new onset difficulty with walking and stammering speech. A brain MRI is normal. You tell him that the first step in his management should be: To increase the CNS penetration of his antiretroviral regimen. Treatment regimen switch given concern for cart side effects. % % % % % % % 8% Physical therapy for gait training. % % First Slide Second Slide HIV Reservoirs in the Brain: Where, When, How, and What Do They Mean for Our Patients? Serena S. Spudich, MD Professor of Neurology Yale University New Haven, Connecticut FORMATTED: //
HIV reservoirs in the brain: Where, when, how, and what do they mean for our patients?
HIV Reservoirs in the Brain: Where, When, How, and What Do They Mean for Our Patients? Serena S. Spudich, MD, MA Professor of Neurology Yale University New Haven, Connecticut FORMATTED: // HIV reservoirs
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationAIDS 2011, 3, 2011 RW
Treating CNS HIV Infection and Disease Why, How and When? Richard W. Price, M.D. Department of Neurology, UCSF/SFGH Preface: Reasons for Renewed Interest in Treatment of CNS HIV Continued CNS infection/disease
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationIAS 2016 Towards an HIV Cure Symposium Durban, South Africa.
Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals treated during acute HIV infection Eugène Kroon, Jintanat Ananworanich,
More informationClinical notes: Management of HAART in patients with HAND
Clinical notes: Management of HAART in patients with HAND Paola Cinque Dipartment of Infectious Diseases San Raffaele Scientific Institute, Milano, Italy 11 Residential Course on Clinical Pharmacology
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationHIV Neurology Persistence of Cognitive Impairment Despite cart
HIV Neurology Persistence of Cognitive Impairment Despite cart Victor Valcour MD PhD Professor of Medicine Memory and Aging Center, Dept. of Neurology University of California San Francisco, USA 8 th International
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationHIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego
HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences
More informationDr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.
BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationAcute HIV Infection. Acute
Acute HIV In nfection n Acute HIV Infection Jintanat t Ananworanich, MD, PhD Investigator, AFRIMS (Armed Forces Research Institute of Medical Sciences) Chief of SEARCH Deputy Director in Scientific Affairs,
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationState of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP
State of the ART: HIV Cure where are we now and ì where are we going? Jintanat Ananworanich, MD, PhD Associate Director for Therapeu1cs Research US Military HIV Research Program (MHRP) Maryland, USA Deputy
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationMHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure
Outline Is HIV cure possible? Ø HIV persistence Cure Strategies Ethical and social considerations Short video on patients perspectives on cure A Case of Cure Off ART Treatment Mechanism Lesson The Berlin
More informationInternational Symposium on. Barcelona, May 5 th and 6 th 2011
th International Symposium on Barcelona, May 5 th and 6 th 2011 Pathogenesis of Neurocognitive Impairment in HIV-infected persons Paola Cinque Dipartimento di Malattie Infettive Istituto Scientifico San
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationCompartmentalized HIV and SIV Populations in the Central Nervous System Are Associated with Neuropathogenesis
Compartmentalized HIV and SIV Populations in the Central Nervous System Are Associated with Neuropathogenesis Gretja Schnell Graduate Student Laboratory of Ronald Swanstrom Department of Microbiology and
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationReview Neurologic Complications of HIV Infection
Review Neurologic Complications of HIV Infection Serena S. Spudich, MD; Beau M. Ances, MD, PhD More than 30 years into the HIV epidemic, research efforts are focusing on better understanding how the central
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationDisclosures 12/7/17. UPDATES IN HIV NEUROLOGY Felicia Chow, MD, MAS University of California, San Francisco December 7, 2017
UPDATES IN HIV NEUROLOGY Felicia Chow, MD, MAS University of California, San Francisco December 7, 2017 Disclosures I have nothing to disclose. Brain Compartment Zayyad et al. Curr HIV/AIDS Rep 2015 Clinical
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationMHRP Studies in Early Treatment and The Journey towards HIV Remission
MHRP Studies in Early Treatment and The Journey towards HIV Remission Merlin L. Robb, MD Deputy Director of MHRP for Clinical Research Director, HJF Component of MHRP US Military HIV Research Program mrobb@hivresearch.org
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationAntiretroviral drug treatment of CNS HIV-1 infection
J Antimicrob Chemother 2012; 67: 299 311 doi:10.1093/jac/dkr492 Advance Access publication 8 December 2011 Antiretroviral drug treatment of CNS HIV-1 infection Aylin Yilmaz 1 *, Richard W. Price 2 and
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationImmunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco
Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationInternational Symposium on. Barcelona, May 5 th and 6 th 2011
th International Symposium on Barcelona, May 5 th and 6 th 2011 4rd Symposium on Psychiatry and HIV --- Barcelona, May 6th 2010 Neurocognitive Testing in HIV Infection: How to Implement this Assessment
More informationHIV & Aging: Evolving Clinical Considerations in the New Millennium
HIV & Aging: Evolving Clinical Considerations in the New Millennium Julian Falutz, MD, FRCP (C) Director, HIV Metabolic Clinic Immunodeficiency Treatment Centre Senior Physician Division of Geriatrics
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationWith over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
More informationOverview. HIV Brain Injury. HIV characteristics. HIV Dementia 11/6/2010
Overview HIV Brain Injury Victor Valcour MD Associate Professor Division of Geriatric Medicine and Department of Neurology/UCSF The neuropathology of HIV HIV Dementia a current snapshot Scenarios of rapid
More informationCure: Early Detection and Early Treatment"
Cure: Early Detection and Early Treatment" ECHO (RV217) and RV 254 Merlin L. Robb, MD, Dr. Jintanat Ananworanich, and Dr. Jerome Kim and Dr. Nelson Michael 4 th International Workshop on HIV & Women 13-14
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationUpdate on Neurologic Complications in Persons With HIV Infection: 2017
Update on Neurologic Complications in Persons With HIV Infection: 2017 FORMATTED: MM/DD/YY Chicago, Illinois: May 10, 2017 Dennis Kolson, MD, PhD Professor of Neurology University of Pennsylvania Philadelphia,
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationAntiviral Therapy 2015; 20: (doi: /IMP2926)
Antiviral Therapy 2015; 20:441 447 (doi: 10.3851/IMP2926) Original article Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationHIV Associated Neurocognitive Disorders in the era of modern CART
HIV Associated Neurocognitive Disorders in the era of modern CART Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego Points to be covered HIV associated
More informationTitle: Distinct Biomarker Signatures in HIV Acute Infection Associate with. Viral Dynamics and Reservoir Size. Supplemental Material
1 2 Title: Distinct Biomarker Signatures in HIV Acute Infection Associate with Viral Dynamics and Reservoir Size 3 Supplemental Material 1 11 12 13 1 1 1 1 1 1 2 21 22 23 2 Authors: Jeffrey E. Teigler
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationPersistent low level viraemia on third line ART
Persistent low level viraemia on third line ART Dr Richard Lessells XXVII International workshop on HIV drug resistance and treatment strategies October 2018 46-year old HIV-positive female HIV diagnosis
More informationCNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz
CNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz Question for the audience Do you think that any integrase inhibitor drug produce CNS adverse
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationDidactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching
Didactic Series Archive Genotype Resistance Testing in the Setting of Regimen Switching Craig Ballard, Pharm.D., AAHIVP UCSD Medical Center Owen Clinic June 11, 2015 ACCREDITATION STATEMENT: University
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationBHIVA Best Practice Management Session
BHIVA Best Practice Management Session CNS (The brain) - I keep forgetting things DEMENTIA DIAGNOSIS, CLASSIFICATION AND INVESTIGATIONS Paul Holmes Consultant Neurologist Guy s and St Thomas Hospitals
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationHIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks
HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationClinical Management of Resistance. AMJ Wensing, MD, PhD
Clinical Management of Resistance AMJ Wensing, MD, PhD Changing treatment paradigm First Line Second Line? New First Line North America Western Europe: Eastern Europe Africa mix South America mix More
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationCerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection
RESEARCH ARTICLE Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection Julia Peterson 1, Magnus Gisslen 2, Henrik Zetterberg 3, Dietmar Fuchs
More informationProfessor Jonathan Weber
HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust
More informationLongitudinal Assessment Of Blood Brain Barrier Disruption In Primary Hiv Infection And Effect Of Cart Therapy
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2017 Longitudinal Assessment Of Blood Brain Barrier Disruption
More informationDynamics of Compartmentalized HIV-1 Populations in the Central Nervous System Patrick R. Harrington
Dynamics of Compartmentalized HIV-1 Populations in the Central Nervous System Patrick R. Harrington Postdoctoral Fellow Laboratory of Ronald Swanstrom Lineberger Comprehensive Cancer Center University
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationDr Jintanat Ananworanich
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationCLAUDINE HENNESSEY & THEUNIS HURTER
HIV/AIDS/TB CLAUDINE HENNESSEY & THEUNIS HURTER KEY TERMS Do these sound familiar? What strange terms do you hear in the clinics? Any others to add?? HIV AIDS Viral Load & suppression CD4 count Regimen
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationSupplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.
Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationAntiviral Therapy 2013; 18: (doi: /IMP2560)
Antiviral Therapy 2013; 18:153 160 (doi: 10.3851/IMP2560) Original article Revised central nervous system neuropenetrationeffectiveness score is associated with cognitive disorders in HIV-infected patients
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationTowards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco
Towards an HIV Cure Steven G. Deeks Professor of Medicine University of California, San Francisco Why are we now talking about a cure? Emerging recognition that HAART does not fully restore health and/or
More informationDiagnosis and Monitoring of HAND
Diagnosis and Monitoring of HAND Norman C. Moore, MD Professor, Director of Research Department of Psychiatry and Behavioral Sciences Quillen College of Medicine APA 2015 Disclosure: Karl Goodkin, MD,
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationGaps between Policy and Practice in Managing HIV disease in Asia Pacific
Gaps between Policy and Practice in Managing HIV disease in Asia Pacific Dr. N. Kumarasamy Chief Medical Officer YRGCARE Medical Centre Voluntary Health Services Chief-Chennai Antiviral Research and Treatment
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationEfavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town
Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More information